Pipeline Overview

Illexcor is advancing its lead drug ILX002, the first and only drug designed to bind to hemoglobin and directly block Hemoglobin S polymerization. Hemoglobin S polymerization inhibitors reduce red blood cell sickling and its associated disease sequalae. ILX002 will begin first-in-human trials upon obtaining IND clearance in the US.

The safety and efficacy of investigational agents have not been established or approved by the FDA or other regulatory authorities.